Congestive Heart Failure - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure
Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries
When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease
Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry
Frailty Is Intertwined With Heart Failure: Mechanisms, Prevalence, Prognosis, Assessment, and Management
Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors

Clinical Trial

2020 Nov 11.

JOURNAL：Circulation.

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

SD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al.

3152

Keywords: cardiorenal outcomes; empagliflozin

Full Text PDF